Jonathan Goodman, MPhil

Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.

The 3-year overall survival rate was 95% with one regimen and 100% with the other.

The 7-year survival results were superior with MATRIX.

The median overall survival was not reached at 3 years.

The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.

The overall response rate was 44.7% after a median follow-up of 15 months.

In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.

The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib

The 12-month overall survival rate was 88%.

Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.